Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-World Use of Recombinant Human TNF Receptor–Fc Fusion Protein in Inflammatory Arthritis
ChiCTR2500115463Phase 4Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Dec 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of etanercept in rheumatoid arthritis (RA), ankylosing spondylitis (AS) and autoimmune arthritis, sponsored by Renji Hospital. Primary endpoint: Proportion of patients achieving clinical remission or low disease activity at 12 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)autoimmune arthritis
Beyond the preview
Go deeper on ChiCTR2500115463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115463.